Twist Bioscience Corp: A Financial Overview and Recent Developments

In the dynamic world of biotechnology, Twist Bioscience Corp has been making headlines with its recent financial disclosures and market activities. As a company specializing in synthetic DNA, Twist Bioscience operates within the Health Care sector and is listed on the Nasdaq. With a market capitalization of $2.01 billion and a close price of $33.68 as of July 31, 2025, the company has been navigating through a challenging financial landscape.

Recent Financial Performance

Twist Bioscience recently announced its fiscal 2025 third-quarter financial results, revealing a mixed picture. The company reported a loss per share of $0.528 for the quarter ending June 30, 2025, which marks an improvement from the $1.470 loss per share in the same quarter of the previous year. Analysts had anticipated this loss, with nine estimating a revenue increase of 17.37% to $95.6 million, up from $81.5 million in the prior year.

Despite the quarterly loss, the company’s revenue growth signals a positive trajectory. For the full fiscal year, analysts project a loss per share of $2.141, an improvement from the $3.600 loss per share in the previous year. Revenue forecasts for the year stand at $376.5 million, compared to $313.0 million in the prior year, reflecting a strategic focus on growth and market expansion.

Leadership and Strategic Focus

Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, emphasized the company’s strong balance sheet and disciplined cost management as key drivers of its focused business execution. The leadership’s commitment to maintaining financial discipline while pursuing growth opportunities is evident in their strategic initiatives and operational adjustments.

Market Sentiment and Insider Activity

The company’s stock has experienced significant volatility, with a 52-week high of $55.33 and a low of $27.12. This volatility is further highlighted by a substantial increase in short interest, which surged by 39,277.3% in July, reaching 10,750,000 shares. The days-to-cover ratio stands at 10.0, indicating heightened market speculation.

Insider activity has also been noteworthy. CEO Emily M. Leproust sold 1,678 shares in June, a transaction valued at $60,005.28, representing a 0.26% decrease in her ownership. Additionally, insider Dennis Cho sold 689 shares in May, valued at $25,940.85. These transactions, disclosed in SEC filings, reflect ongoing insider confidence in the company’s long-term prospects despite short-term market fluctuations.

Looking Ahead

Twist Bioscience is poised to continue its journey in the biotechnology sector, leveraging its expertise in synthetic DNA to address diverse applications in biodetection, functional genomics, genome engineering, and more. As the company navigates through financial challenges and market dynamics, its strategic focus on innovation and operational efficiency will be crucial in driving future growth and shareholder value.

For more detailed insights, stakeholders are encouraged to review the company’s earnings report and investor presentation available on their Investor Relations website. The upcoming conference call, scheduled for 8:00 a.m. Eastern Time, will provide further updates on the company’s financial results and strategic direction.